RLY-4008
Relay Therapeutics
['agent', 'focus v', 'rly-4008', 'refocus']
refocus validates rly-4008 as active agent for fgfr2+ cholangiocarcinoma #esmo2022 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.